| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | 0.17 | 0.002 |
| mRNA | UNC0638:navitoclax (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.12 | 0.002 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | 0.18 | 0.002 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.12 | 0.003 |
| mRNA | CAY10618 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.003 |
| mRNA | chlorambucil | CTRPv2 | pan-cancer | AAC | 0.1 | 0.003 |
| mRNA | Bexarotene | GDSC1000 | pan-cancer | AAC | -0.11 | 0.003 |
| mRNA | Obatoclax Mesylate | GDSC1000 | pan-cancer | AAC | 0.1 | 0.003 |
| mRNA | NVP-231 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.003 |
| mRNA | GSK1070916 | GDSC1000 | pan-cancer | AAC | 0.095 | 0.003 |